This session will explore the collection and use of COVID-19 convalescent plasma (CCP). Dr. Sachais will describe his center’s experience as a blood collection center during COVID-19 and address and describe issues with implementing a CCP program. Dr. Simon will describe the experience of plasma collection centers in the plasma consortium during COVID-19 and the implementation of a CCP collection program. Speakers will address donor recruitment and collection issues including trends across the country in CCP collection. The selection criteria for CCP donors will be discussed. Speakers will describe methods used to test donor antibody levels and describe trends in antibody decline over time. Effect of ethnicity, gender and other donor characteristics on COVID-19 antibody levels and decline will be presented. Differences in total and neutralizing antibodies will be discussed. The use and efficacy of CCP to treat COVID-19 in different patient populations will be summarized.
To view Spanish or English subtitles, click the "CC" box in the video player. Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Discuss the advantages and disadvantages of different methodologies used in measuring COVID-19 convalescent plasma (CCP) antibody levels
Summarize the difference between COVID-19 overall antibody level and COVID-19 neutralizing antibody levels and which donors have better overall and/or neutralizing antibodies
Describe the differences in COVID-19 antibody levels in donors based upon gender, ethnicity, region, and time since infection
Describe the correlation between the donor's CCP antibody level and the clinical impact/outcome for the recipient.
Describe issues and difficulties around recruiting and retaining COVID-19 convalescent plasma donors